Narmac, I completely disagree with your post. 1)jmo but I think "funds" do not invest in RVX because of uncertainty/risk of cutting edge science, and secondly because establishing any meaningful position in RVX on the open market, say 1% of the company, would drive the share price sky high and the position would likely become immediately illiquid post purchase, for all intents and purposes. 2)I think the biggest mistake RVX could make would be to do a highly dilutive financing to clear the loan when there are likely other far less dilutive alternatives available. My biggest question would be, if RVX went to an outside party to do this type of private placement financing who amongst existing shareholders wins? Nobody. Eastern, Hepalink, NGN, management and us retailers would all experience heavy dilution to clear a loan that doesn't need clearing. In 2017 if Eastern wanted too much in return for extended loan guarantees I'm fairly certain Don could get Hepalink to take the collateral and warrants in exchange for the guarantees. In any event, with two existing deep pocket investors, the process is likely to be competitive. Additionally, thus far without a competitor, Eastern has been very reasonable and fair in its support of RVX. I'm not sure why this should be expected to change